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GObjectives: To compare the clinical- and cost-
effectiveness of minimally invasive direct coronary
artery bypass grafting (MIDCAB) and percutaneous
transluminal coronary angioplasty (PTCA) with or
without stenting in patients with single-vessel disease of
the left anterior descending coronary artery (LAD).
Design: Multi-centre randomised trial without blinding.
The computer-generated sequence of randomised
assignments was stratified by centre, allocated
participants in blocks and was concealed using a
centralised telephone facility. 
Setting: Four tertiary cardiothoracic surgery centres in
England.
Participants: Patients with ischaemic heart disease
with at least 50% proximal stenosis of the LAD,
suitable for either PTCA or MIDCAB, and with no
significant disease in another vessel.
Interventions: Patients randomised to PTCA had local
anaesthetic and underwent PTCA according to the
method preferred by the operator carrying out the
procedure. Patients randomised to MIDCAB had
general anaesthetic. The chest was opened through an
8–10-cm left anterior thoracotomy. The ribs were
retracted and the left internal thoracic artery (LITA)
harvested. The pericardium was opened in the line of
the LAD to confirm the feasibility of operation. The
distal LITA was anastomosed end-to-side to an
arteriotomy in the LAD. All operators were
experienced in carrying out MIDCAB.
Main outcome measures: The primary outcome
measure was survival free from cardiac-related events.
Relevant events were death, myocardial infarction,
repeat coronary revascularisation and recurrence of
symptomatic angina or clinical signs of ischaemia during
an exercise tolerance test at annual follow-up.
Secondary outcome measures were complications,
functional outcome, disease-specific and generic quality
of life, health and social services resource use and their
costs.
Results: A total of 12,828 consecutive patients
undergoing an angiogram were logged at participating
centres from November 1999 to December 2001. Of
the 1091 patients with proximal stenosis of the LAD,
127 were eligible and consented to take part; 100 were
randomised and the remaining 27 consented to follow-
up. All randomised participants were included in an
intention-to-treat analysis of survival free from cardiac-
related events, which found a non-significant benefit
Health Technology Assessment 2004; Vol. 8: No. 16
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Tropical Medicine, London, UKfrom MIDCAB. Cumulative hazard rates at 12 months
were estimated to be 7.1 and 9.2% for MIDCAB and
PTCA, respectively. There were no important
differences between MIDCAB and PTCA with respect
to angina symptoms or disease-specific or generic
quality of life. The total NHS procedure costs were
£1648 and £946 for MIDCAB and PTCA, respectively.
The costs of resources used during 1 year of follow-up
were £1033 and £843, respectively.
Conclusions: The study found no evidence that
MIDCAB was more effective than PTCA. The
procedure costs of MIDCAB were observed to be
considerably higher than those of PTCA. Given these
findings, it is unlikely that MIDCAB represents a cost-
effective use of resources in the reference population.
Recent advances in cardiac surgery mean that surgeons
now tend to carry out off-pump bypass grafting via a
sternotomy instead of MIDCAB. At the same time,
cardiologists are treating more patients with multi-
vessel disease by PTCA. Future primary research
should focus on this comparison. Other small trials of
PTCA versus MIDCAB have now finished and a more
conclusive answer to the original objective could be
provided by a systematic review.
Abstract
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List of abbreviations
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.Objectives
To compare the (a) clinical and (b) cost-effectiveness
of minimally invasive direct coronary artery bypass
grafting (MIDCAB) and percutaneous transluminal
coronary angioplasty (PTCA) with or without
stenting in patients with single-vessel disease of the
left anterior descending coronary artery (LAD).
Design
Multi-centre randomised trial without blinding.
The computer-generated sequence of randomised
assignments was stratified by centre, allocated
participants in blocks and was concealed using a
centralised telephone facility. 
Setting
Four tertiary cardiothoracic surgery centres in
England.
Participants
Patients with ischaemic heart disease with ≥ 50%
proximal stenosis of the LAD, suitable for either
PTCA or MIDCAB, and with no significant disease
in another vessel.
Interventions
Patients randomised to PTCA had local
anaesthetic and underwent PTCA according to the
method preferred by the operator carrying out the
procedure.
Patients randomised to MIDCAB had general
anaesthetic. The chest was opened through an
8–10-cm left anterior thoracotomy. The ribs were
retracted and the left internal thoracic artery
(LITA) harvested. The pericardium was opened in
the line of the LAD to confirm the feasibility of
operation. The distal LITA was anastomosed end-
to-side to an arteriotomy in the LAD. All
operators were experienced in carrying out
MIDCAB.
Main outcome measures
The primary outcome measure was survival free
from cardiac-related events. Relevant events were
death, myocardial infarction, repeat coronary
revascularisation and recurrence of symptomatic
angina or clinical signs of ischaemia during an
exercise tolerance test at annual follow-up.
Secondary outcome measures were complications,
functional outcome, disease-specific and generic
quality of life, health and social services resource
use and their costs.
Results
Participants were recruited from November 1999
to December 2001; 1091 of 12,828 consecutive
patients undergoing a diagnostic angiogram or
elective PTCA had proximal stenosis of the LAD.
Of the 1091, 127 were eligible and consented to
take part; 100 were randomised and the
remaining 27 consented to follow-up. 
All randomised participants were included in an
intention-to-treat analysis of survival free from
cardiac-related events, which found a non-
significant benefit from MIDCAB (hazard ratio =
0.77, 95% confidence interval 0.38 to 1.57, 
p = 0.47). Cumulative rates of cardiac-related
events at 12 months were estimated to be 7.1 and
9.2% for MIDCAB and PTCA, respectively. There
were no important differences between MIDCAB
and PTCA with respect to angina symptoms or
disease-specific or generic quality of life.
The total NHS procedure costs were £1648 and
£946 for MIDCAB and PTCA, respectively. The
costs of resources used during 1 year of follow-up
were £1033 and £843, respectively.
Conclusions
We found no evidence that MIDCAB was more
effective than PTCA. However, the trial did not
have sufficient power and we cannot rule out this
possibility. The procedure costs of MIDCAB were
considerably higher than those of PTCA. Given
the small and non-significant differences in
Health Technology Assessment 2004; Vol. 8: No. 16
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Executive summaryeffectiveness between MIDCAB and PTCA and the
considerably higher costs of MIDCAB, it is
unlikely that MIDCAB represents a cost-effective
use of resources in the reference population.
Recent advances in cardiac surgery mean that
surgeons now tend to carry out off-pump bypass
grafting via a sternotomy instead of MIDCAB. At
the same time, cardiologists are treating more
patients with multi-vessel disease by PTCA. Future
primary research should focus on this comparison.
Other small trials of PTCA versus MIDCAB have
now finished and a more conclusive answer to the
original objective could be provided by a
systematic review.
Executive summary
xBackground
Treatment of coronary heart disease is a very
important area of healthcare to the NHS.1 It is
generally accepted that interventional treatment is
indicated for proximal stenosis of the left anterior
descending coronary artery (LAD). For these
patients, the two main established treatment
procedures are coronary artery bypass grafting
(CABG) and percutaneous transluminal coronary
angioplasty (PTCA), which are both effective,
although PTCA is less invasive and cheaper. Both
PTCA and conventional CABG [grafting the left
internal thoracic artery (LITA) to the LAD] are
more effective than medical therapy in relieving
symptoms and improving survival.2–4 An
alternative procedure with equal or better
effectiveness could achieve substantial savings for
the NHS; savings could arise either because the
primary procedure itself was less expensive, or
because its improved effectiveness obviated the
need for subsequent medical or surgical therapies.
In the current era, PTCA with stenting is the most
widely used treatment for isolated stenosis of the
LAD because the early clinical outcomes after
PTCA are similar to those after CABG and PTCA
has relatively low cost and patients recover rapidly.
However, the main drawback of PTCA is the risk
of restenosis. Up to 30% of patients who undergo
PTCA may suffer a recurrence of their symptoms
within 1 year, many of whom require a further
intervention with increased requirements for
repeat angiography, PTCA or CABG surgery.
However, like surgery, the techniques and
materials used for PTCA are evolving with
continuing improvements in outcome, for
example, angioplasty with and without stenting
and different types of stent.5,6 In addition to this
problem, the outcome for certain types of lesion
(type C) may be worse after PTCA.7
Minimally invasive direct
coronary artery bypass
In recent years, minimally invasive direct coronary
artery bypass (MIDCAB) grafting has been
developed for treating patients with proximal
stenosis of the LAD.8–10 This operation involves a
small left anterior thoracotomy and anastomosis of
the LITA to the LAD by direct suture.8–10 It is
performed either on the beating heart with the
use of stabilising devices or using a minimal access
bypass system with endo-aortic clamping and
cardioplegic arrest (Heartport Inc., USA).11 It
appears increasingly accepted that, although
complex minimally invasive bypass systems may be
crucial to the development of more complex
intracardiac operations, single-vessel
revascularisation of the LAD can be performed in
experienced hands on the beating heart without
cardiopulmonary bypass.
Preliminary case series8,9,12 indicate that MIDCAB
is safe, relatively cheap and less invasive than
CABG, and potentially more effective than PTCA.
Peri-operative complications (mortality, 0.6%; 
re-operation, 1.2%8) are less frequent than with
CABG, and of a similar frequency to angioplasty.
However, given the sample size of existing case
series, this aspect of the technique needs to be
investigated carefully as experience increases. In
~5% of patients, the MIDCAB technique may be
deemed unsuitable, and the procedure has to be
converted to a standard procedure.8,9 MIDCAB
appears to give good anastomotic patency, relief of
symptoms and short hospital stays with the
promise of a long-lasting result based on the
known longevity of LITA grafting after
conventional CABG surgery.8,9
The promising results from case series using
MIDCAB8,9,12 demonstrate the need for a formal
evaluation to compare the effectiveness and cost-
effectiveness of current practice, that is, PTCA,
with MIDCAB. Preliminary data from the single
prospective observational study indicate that the
risk of re-intervention after MIDCAB is much
lower than after PTCA.12 Therefore, there is a
clear case for a randomised controlled trial (RCT)
of the clinical and cost-effectiveness of MIDCAB
versus PTCA for the treatment of isolated stenosis
of the LAD.
Objectives
The objectives of the study were to compare the
(a) clinical effectiveness and (b) cost-effectiveness
Health Technology Assessment 2004; Vol. 8: No. 16
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Chapter 1
Introductionof MIDCAB and PTCA with stenting, if
appropriate, in patients with single vessel disease
of the LAD using an RCT study design. We
hypothesised that MIDCAB would have better
clinical effectiveness than PTCA with respect to
survival free from cardiac-related events 1 year
after treatment.
Introduction
2Participating centres
The Angioplasty versus Minimally Invasive
Surgery Trial (AMIST) was carried out in several
centres. Six cardiac centres agreed to take part
when the study was planned: 
  United Bristol Healthcare NHS Trust, Bristol
Royal Infirmary (Bristol)
  Glenfield NHS Trust, Leicester (Leicester)
  Central Manchester Health NHS Trust,
Manchester Royal Infirmary (Manchester)
  St Mary’s NHS Trust, St Mary’s Hospital,
London (London)
  Papworth Hospital NHS Trust, Cambridge
(Papworth)
  Leeds NHS Trust, Leeds General Infirmary
(Leeds).
Bristol was the coordinating centre for the study.
At least one surgeon in each of the centres had
substantial experience of MIDCAB. When AMIST
started recruiting, all centres performed at least
750 PTCA procedures per year.
Study population
The reference study population was all patients
with proximal stenosis of the LAD, suitable for
either PTCA or MIDCAB, with no significant
disease in any other vessel. Patients were recruited
from those undergoing a diagnostic angiogram or
elective PTCA.
Eligibility criteria
The suitability of patients for PTCA dictated the
selection criteria (below), and the lesion had to be
judged technically suitable for PTCA by at least
one senior operator:
1. There had to be evidence of ischaemia, either
by exercise test or isotope perfusion scan
(except for patients with unstable angina, in
whom there should be ECG changes during
exercise).
2. The lesion had to be at least 50% diameter
stenosis (or 75% cross-sectional area) by visual
assessment or quantitative coronary
angiography.
3. The lesion had to lie in the proximal half of
the LAD.
4. There had to be a significant segment of
normal vessel (at least twice the vessel
diameter) lying between the lesion and the
distal left main coronary artery.
5. The lesion should not involve or compromise a
major graftable side branch.
6. Anterograde flow through the lesion had to be
demonstrable.
Both elective and ‘urgent’, but not emergency,
patients were eligible. Emergency patients were
defined as those for whom an intervention was
required within 24 hours. Urgent patients
included those with unstable angina. Urgent
patients were included because they constitute a
large proportion of PTCA patients (up to 50%),
and are suitable for either PTCA or MIDCAB.
Patients who required emergency intervention
within 24 hours of angiogram were excluded from
the study. All inclusion and exclusion criteria are
summarised in Table 1.
The eligibility of elective patients was determined
from the usual clinical investigations, for example,
exercise tolerance test (ETT) or diagnostic
angiography. The eligibility of urgent patients was
determined at angiography following admission.
For urgent patients, PTCA or MIDCAB was
carried out during the same admission.
Reliability of the application of the eligibility
criteria was estimated by comparing the
judgements of a cardiologist and cardiac surgeon,
who independently reviewed the angiograms of
the first 100 patients who were believed to have
proximal stenosis of the LAD.
Target sample size with justification
The primary outcome was the rate of event-free
survival at 12 months. The proportion of patients
undergoing PTCA and MIDCAB expected to
experience a cardiac-related event or death in the
first year after the procedure was uncertain when
the study was designed. One recent paper had
indicated that 14 ± 9% of patients undergoing
angioplasty with stenting suffer a cardiac-related
clinical event or a recurrence of angina within 
1 year,13 but larger studies had reported failure
Health Technology Assessment 2004; Vol. 8: No. 16
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Chapter 2
Methodsrates of 20 ± 4%.5,14 Case series of patients who
had undergone MIDCAB had reported 
recurrence of symptoms in 3 ± 4%10 and 8 ± 4%
of patients.9
On the basis of the literature, we suggested that
plausible expected risks of events were 6% for
MIDCAB and 16% for angioplasty with stenting
after 1 year of follow-up. We proposed that the
study should be designed to detect a difference in
the rate of recurrence of symptoms of 10%. Table 2
shows the sample sizes (5% significance level, two-
tailed and for both 80 and 90% power) required to
detect a 10% difference in the risk of an event for
different absolute levels of risk for MIDCAB and
PTCA, assuming an analysis comparing the
number of events observed in the two groups. On
the basis of these calculations, we set a target
sample size of 360. This sample size would have
allowed the study to detect a standardised
difference in continuous outcomes [symptom and
quality of life (QoL) scores] of 0.3 with 80% power
at a 5% (two-tailed) significance level.
The sample sizes shown in Table 2 are based on
‘risk’ analyses. At the outset, we planned that trial
Methods
4
TABLE 1 Summary of inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
A significant segment of normal vessel (at least double
the vessel diameter) lies between the lesion and the
distal left main coronary artery
Certainty that the lesion does not involve or
compromise a major graftable side branch
LAD lesion has stenosis at least 50% diameter (or
75% cross-sectional area) by visual assessment or
quantitative coronary angiography
Lesion lies in the proximal half of the LAD
Patient has a lesion of the LAD (left anterior
descending) that is suitable for angioplasty
Patient has angina
Patient shows clinical evidence of ischaemia
There is demonstrable anterograde flow through the
lesion
Aortic/mitral regurgitation, grade III/IV
Body mass index >34
Disease in a major coronary vessel other than the LAD requiring
intervention
Evidence of severe thoracic disease or bullous emphysema on
chest X-ray or history of chronic obstructive pulmonary disease as
indicated by forced expiratory volume <40%
History of pericarditis, median sternotomy, thoracotomy, chest
irradiation or pleurodesis
Known bleeding diathesis
Left ventricular impairment (angiogram or echocardiography
indicating ejection fraction <30%)
Malignant hypertension necessitating hospitalisation, or systolic
blood pressure >240 mmHg within the previous 30 days
Marfan’s syndrome or related connective tissue disorder
Patient participating in another research study
Patient unable to comply with the requirements of the protocol
Previous CABG
Previous PTCA/stent in the proximal LAD
Symptomatic cerebrovascular disease
Significant stenotic valve disease
Transmural MI during the past month
Uncontrolled diabetes as indicated by more than three serum
glucose concentrations >350 mg/dl within the previous 7 days
TABLE 2 Sample sizes required to detect a 10% difference in
the risk of an adverse event for different levels of baseline risk
and power
PTCA vs MIDCAB 80% power 90% power
18 vs 8% 350 470
16 vs 6% 330 440
14 vs 4% 250 340data about cardiac-related events would be
analysed by survival methods, allowing periods of
follow-up longer than 1 year to be included. Using
survival analysis means that the trial would have
had slightly greater power than indicated for the
given sample sizes.
Recruitment and randomised
assignment
Recruitment
In each centre, a log was kept on a daily basis
documenting the demographic and clinical
characteristics of all patients undergoing an
angiogram (hospital number, gender, date of
birth, ethnicity and diagnoses). These logs were
maintained by the research nurses. Patients
diagnosed with single vessel disease of the LAD
were initially assessed against the eligibility criteria
for the trial by the research nurse. If a patient
appeared to be eligible after this assessment, a
cardiologist checked the angiographic eligibility
criteria and, if in the cardiologist’s opinion the
patient satisfied these criteria, eligibility was
checked with one of the surgeons experienced in
carrying out MIDCAB.
Patients considered eligible by both a cardiologist
and a cardiac surgeon were given the Patient
Information Sheet and received an explanation of
the trial from the cardiologist or surgeon. At least
24 hours usually elapsed between patients
receiving the Patient Information Sheet and being
asked to consent, but this was not always possible
for urgent patients. 
Information about the study was given to urgent
patients after they had had their angiograms and
their consent to be randomised was sought shortly
afterwards; for these patients, PTCA or MIDCAB
was carried out during the same admission. This
arrangement was not ideal, since it required urgent
patients to make a decision about joining the
study quickly and at a time when they were likely
to be anxious because of their clinical condition.
However, we believed that it was important to
include urgent patients to make the findings of the
trial more applicable and we presented the case
for doing so in our applications to a Multi-centre
and Local Research Ethics Committees.
Patients were asked to sign two copies of the
consent form. One copy was given to the patient
and the other was filed with the patient’s medical
records. Both copies were also signed by either a
cardiologist or cardiac surgeon. Once the consent
form had been signed, the treatment allocation for
the patient was obtained by telephoning the
automated randomisation facility at the
coordinating centre.
The consent forms allowed patients to consent to
randomisation and follow-up separately. If an
eligible patient did not consent to being
randomised, he or she was asked to consent to
being followed up in the same way as randomised
patients (see ‘Data collection procedures’, p. 7).
Once a patient had signed the consent form
(either for randomisation and follow-up, or for
follow-up only), a letter was sent to the patient’s
GP to notify him or her that the patient had
agreed to participate in AMIST.
Randomised assignment
The sequence of randomised assignments for the
trial was generated in advance by computer. The
sequence was stratified by centre and allocated
participants in blocks of unequal length (block
lengths of two, four, six and eight; varied block
length was used to preserve masking of treatment
allocation, since the trial was not blinded) to
balance the numbers in the two arms of the trial
better than would be expected with simple
randomisation. The assignments were held in a
computer which participating centres accessed by
telephone. Study numbers, dates of calls and the
interventions allocated were recorded by the
computer software.
Allocation was concealed by virtue of the
assignments being held in the computer. The
assignments could not be viewed. Assignments
were disclosed strictly in accordance with the
predetermined sequence for each centre and the
next assignment was only disclosed in response to a
telephone call to the central randomisation facility.
Generation of the sequence of randomised
assignments for the trial was implemented by the
company that provided the central telephone
randomisation facility. Participants were enrolled
by study nurses and clinicians in each centre as
described above.
Patients who agreed to be followed up but who did
not consent to randomisation were not registered
on the central telephone randomisation facility.
Instead, centres telephoned the trial coordinator in
Bristol for an identification number for a patient.
Every effort was made by centres to carry out the
intervention that was assigned to a patient within
1 month.
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Percutaneous transluminal coronary
angioplasty (PTCA)
Patients randomised to PTCA were given a 
local anaesthetic and PTCA was carried out
according to the method preferred by the
operator carrying out the procedure. At the 
outset, the use of stenting in conjunction with
PTCA was a crucial consideration in view of
evidence that stenting improves the outcomes 
of PTCA.5,13,14 At the same time, cardiologists 
felt that it was important to recognise that 
stenting is not clinically necessary for a 
minority of patients. It was therefore 
agreed that cardiologists would use stents 
for all patients for whom they judged 
stenting was required. Clinical indications for
stenting were identified under three main
headings:
  ‘Bail out’: the need for stenting arises from
severe disruption of the vessel lumen
compromising flow at the time of the
procedure.
  Sub-optimal result: the need for stenting 
arises because of significant residual stenosis,
filling defect, asymmetry of the lesion or
impairment of flow, despite there being 
no signs of ischaemia during the 
procedure.
  Elective stent: the characteristics of the lesion
(large plaque, eccentric lesion, long lesion, etc.)
merit a decision to stent before the first
dilatation.
Clinical indications for leaving a patient without a
stent were also identified, i.e. no residual stenosis,
filling defect or irregularity on a check angiogram
taken at least 5 minutes after the wire has been
removed.
All patients undergoing PTCA received the
following medications:
  ticlopidine 250 mg twice daily, to start 48 hours
before PTCA, if possible, and for 4 weeks
following PTCA
  aspirin 150–300 mg daily, continuing for the
patient’s lifetime unless contraindications
develop
  heparin during the procedure only, using a
titrated dose to maintain a 300-second clotting
time.
Patency of the vessel was assessed by angiography
after the procedure was completed. 
Minimally invasive direct coronary
artery bypass graft (MIDCAB)
Patients randomised to MIDCAB were operated
on using the following procedure. Under general
anaesthesia, the chest was opened through an
8–10-cm incision in the fourth or fifth intercostal
space. The ribs were retracted and the LITA
harvested, either under direct vision or using
thoracoscopic assistance. The pericardium was
then opened in the line of the LAD to confirm the
feasibility of the operation via limited access.
The patient was systemically heparinised (1 mg/kg),
the coronary artery immobilised and blood flow
controlled by placing encircling snares proximally
and distally. The distal LITA was then
anastomosed end to side to an arteriotomy in the
LAD. After completing the anastomosis, the
heparin was reversed with protamine and the
chest closed in layers, leaving a single drain 
within it.
When the trial was proposed, MIDCAB had been
used successfully by the lead applicant9 and
colleagues. In a series of 155 patients, patency was
demonstrated in 96% immediately postoperatively
and the event-free survival rate over 1 year was
estimated to be 92%. Approximately 250 MIDCAB
procedures had been carried out in the planned
six participating centres.
Description of outcomes
The primary outcome measure was survival free
from cardiac-related events, that is, a combined
outcome of all-cause death or a cardiac-related
event. Relevant cardiac-related events were
defined as: 
  myocardial infarction (confirmed by
electrocardiographic findings)
  repeat revascularisation (either PTCA or cardiac
surgery)
  recurrence of symptomatic angina
  recurrence of angina evidenced by findings of
ischaemia during an ETT at the annual follow-up.
The following secondary outcome measures were
also defined in the protocol, although the
instruments used to measure these outcomes were
reviewed before starting the trial (see ‘Outcomes’,
p. 11):
  Complications of the index procedure, including
the need for a further revascularisation
procedure.
Methods
6  Functional outcome, measured using the Seattle
Angina Questionnaire (SAQ)15,16 (a self-
completion questionnaire) at 3, 6 and 
12 months after the index intervention, and by
an ETT using the Bruce protocol at 12 months.
Standard features of the ETT were documented,
that is, exercise duration, time to onset of
angina pain and time to 1-mm segment
depression in any given lead.
  Generic QoL, measured using the General Well-
being Index17,18 and the EuroQol/EQ5D19,20
(self-completion questionnaires) at 3, 6 and 
12 months. The General Well-being Index had
been used previously to assess anxiety and
depression in patients with cardiovascular
disease.21 The EuroQol was included because it
provides a QoL utility measure.
Data describing the use of health and social
services, including all secondary/tertiary care,
investigations subsequent to discharge following
the index procedure, contacts with GPs and other
members of the primary care team and care in the
home given by social services, prescribed
medications and the associated costs of these
resources were also collected for the economic
evaluation (see ‘Economic evaluation’, p. 9). 
Previous studies of this kind have often used
patency of the treated vessel at follow-up as an
outcome measure, for example, angiography. We
did not assess patency at 1 year because (a)
patency is not the primary concern of patients, 
(b) angiography has a high cost (at least £500 per
patient when the trial was designed) and (c) we
had ethical concerns about requiring
asymptomatic patients to undergo angiography,
which carries a small risk of morbidity and
mortality.
Blinding
It will be clear from the descriptions of the
interventions (see ‘Description of interventions’, 
p. 6) that neither the surgeons and cardiologists
providing the interventions nor the patients could
be blinded. For example, one intervention
required a general anaesthetic and involved a
chest wound (MIDCAB) and the other required a
local anaesthetic and involved a groin wound
(PTCA).
However, we proposed to blind the assessment of
the primary outcome, that is, the occurrence of
cardiac-related events, and to ask a cardiologist
and a cardiac surgeon to carry out independent
‘adjudication’ of possible cardiac-related events.
Unfortunately, it quickly became clear that it was
not possible to blind outcome assessment (see
‘Outcomes’, p. 11). 
In order to obtain informed consent from
participants, it was necessary to describe the aim
of the study and the nature of the two
interventions being compared. Therefore, patients
also were not blind to the treatment allocation
when they completed questionnaire outcomes.
All potential adverse events were also sent to the
cardiologist and a cardiac surgeon for
independent review.
Data collection procedures
Demographic and clinical details of participants
were recorded on a standard form when they were
recruited to the study; these details included date
of birth, gender, ETT and angiography findings,
medications, and whether or not a patient was
hypertensive or diabetic. ETTs were assessed
preoperatively, as part of the normal clinical
practice prior to MIDCAB or PTCA.
Procedural details, including complications (death
in hospital, myocardial infarction, arrhythmias,
bleeding, transfusion, wound infection or
inflammation, postprocedural persistent angina,
taken to operating theatre after the index
procedure), deviations from the planned
procedure (including conversions to surgery from
PTCA or conversion from MIDCAB to
conventional CABG) and theatre/catheter
laboratory resources used were documented at the
time of the index procedure. Other hospital
resources used during admission for the index
procedure were also recorded.
Patients collected data about their use of health
and social services in monthly ‘diaries’. The
research nurse in each centre collected the
information monthly either by a telephone call
(months 1, 2, 4, 5 and 7–11) or by sending a
questionnaire to patients for them to complete
(months 3, 6 and 12, coinciding with the
collection of functional and QoL data).
The SAQ and other QoL questionnaires were
completed by patients before undergoing their
assigned procedures and at 3, 6 and 12 months.
The questionnaires were printed as a single A4
booklet and were sent to patients with a covering
letter, enclosing a prepaid reply envelope. The
front page stated the patient’s name and study ID
number. If a patient did not return the booklet
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nurse telephoned to make sure that the patient
had received it. If the booklet had not been
received, the nurse sent another one with a
covering letter and prepaid reply envelope. If a
patient returned the booklet but had missed some
of the questions, the research nurse called the
patient to try to obtain the missing information. If
a patient did not return the booklet within 7 days
of sending the reminder (or within days of the
reminder telephone contact), the research nurse
telephoned again and, if possible, collected the
information requested in the booklet over the
telephone.
During follow-up, adverse events were documented
from clinical records and by contacting patients
and, if necessary, their GPs. Research staff were
alerted to the occurrence of adverse events from
healthcare contacts recorded in patients’ diaries.
ETTs were carried out at 1 year for event-free
patients whenever this was possible. Some patients
had requested to withdraw from further follow-up
by this time and, for some patients, 1 year had not
elapsed from the time of the index procedure
when data collection ceased.
Research nurses continued to follow up patients
who had survived the first year following their
procedures without experiencing an event by
sending a short questionnaire every 3 months
requesting information about hospital admissions,
recurrence of angina symptoms or other major
disease events.
We originally proposed that all patients
experiencing a recurrence of symptoms should be
reassessed angiographically when they are re-
referred, as part of their normal clinical
management. Unfortunately, it was not always
possible to ensure that an angiogram was carried
out in these circumstances (see ‘Outcomes’, p. 11).
Research governance
The study was approved by the South West Multi-
centre Research Ethics Committee on 14 May
1999 (ref. MREC/99/6/24). 
A Data Monitoring Committee (DMC) was
established at the start of the trial and first met on
3 March 2000. The DMC consisted of: 
  Mr Stephen Evans, Consultant Cardiologist,
Trelisk Hospital, Truro, Cornwall
  Mr Bruce Keogh, Consultant Cardiothoracic
Surgeon of University Hospital Birmingham
(Chairman)
  Dr Barnaby Reeves, Senior Lecturer in
Epidemiology, London School of Hygiene and
Tropical Medicine and co-investigator with the
Angioplasty versus Minimally Invasive Surgery
Trial (AMIST)
  Dr Robert West, Reader in Epidemiology,
University of Wales College of Medicine
  Mr Ian White, Lecturer in Medical Statistics,
London School of Hygiene and Tropical
Medicine.
Although Dr Reeves was a co-investigator, he was
not involved in the data collection for AMIST and
attended the DMC meeting in order to provide
any additional information about the trial that
other members of the DMC might require. He did
not participate in decisions made by the DMC.
One interim analysis was planned. The DMC
defined the following rule for stopping AMIST on
the basis of the interim analysis: 
“The trial will be stopped if a difference between
groups is observed in a single, planned interim
analysis with respect to the primary outcome at a
significance level of p < 0.001; the interim analysis
should be carried out approximately 3 months after
50% of the target sample size has been recruited
(giving a median follow-up of about 6 months for the
first 50% of recruited patients).”
The DMC concluded that the date of the interim
analysis could not be set at the outset because of
uncertainty about the recruitment rate.
Statistical analyses
Reliability of the application of the eligibility
criteria and the adjudication of cardiac-related
events (see ‘Outcomes’, p. 11) was estimated using
Cohen’s kappa statistic ( ).22
For the primary outcome, that is, survival free
from death or a cardiac-related event, Cox
proportional hazards analyses were carried out,
entering into the model only the variable
describing the intervention. The date of entry was
the date of randomisation. The date of censoring
for patients who did not experience any cardiac-
related event and who survived to the end of the
trial was either 30 June 2002 for patients who had
not reached 1 year of follow-up or the date of last
known follow-up (i.e. date of last 3-month follow-
up form completed) for patients who had been
Methods
8followed up for more than 1 year. Patients who
died or who experienced a cardiac-related event
did not contribute survival time after the date of
the first event. Cumulative hazard estimate graphs
are presented for the first 2 years of follow-up
only.23
Regression modelling was used to analyse other
data on effectiveness, that is, the SAQ and other
QoL instruments, adjusting estimates of
differences between groups for baseline scores.
Regression diagnostic tests were inspected. The
use of multiple regression assumes that QoL scores
are parametric, an assumption which is usually
made for data from the instruments that were
used. The potential for increasing precision of
estimates of differences between groups was a
further justification for using regression.
Intention-to-treat (ITT) analyses were carried out
for all outcomes. A secondary analysis of the
primary outcome was also carried out according to
the treatment received, including non-randomised
patients (in which the date of ‘entry’ was set to be
the date of the intervention) but excluding two
patients who did not receive either intervention.
Statistical significance was set at 5% (two-tailed)
for all inferential tests.
Economic evaluation
The economic assessments were based on data
that were collected on the resources used in
MIDCAB and PTCA procedures. These included
the length of stay on wards in total and after the
procedure, drugs prescribed at admission,
discharge and after discharge, theatre time of staff
and equipment used in procedures and health and
social services resources used by patients during
follow-up. 
These resources were costed using data collected
from the Bristol Royal Infirmary, Personal Social
Services Research Unit data on staff costs,
formulary costs of prescriptions from the British
National Formulary (www.bnf.org.uk) and costing
data for tests from laboratories. Data were also
collected on travel costs and out-of-pocket
expenses of patients and the number of days that
patients and carers had to take off work; a cost was
imputed to this time using average wage rates
recorded in the New Earnings Survey.24 Economic
data are often highly skewed, which may limit the
validity of conventional statistical methods used to
derive point estimates and confidence intervals
(CIs), especially when sample sizes are small. To
overcome this disadvantage, sensitivity analysis was
undertaken to assess the robustness of the
findings, whereby costs were varied by ±10–50%.
In addition, calculations were made to assess the
changes required to create equivalence in costs
between the two procedures for the key variables.
Cost data on tests used as part of the standard
work-up and medications on admission were
excluded from the final analysis, as they should
not differ between the two treatment arms. This
assumption was borne out by the data (see Table 3)
that showed no significant difference in these costs
for the two treatment arms.
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TABLE 3 Costs of ‘work-up’ tests and medications at the time of admission
PTCA: MIDCAB:  Difference p-Value
mean (SD) (£) mean (SD) (£) (95% CI) (£)
Tests 58.64 58.48 0.16 0.94
(11.79) (8.91) (–4.02 to 4.34)
Medications at admission 43.99 38.53 5.46 0.25
(24.46) (22.00) (–3.85 to 14.77)Participating centres
The original proposal submitted by Bristol
included three centres, namely Bristol, Leicester
and Manchester, and proposed to recruit
participants over a period of 2 years. The NHS
R&D National Coordinating Centre for Health
Technology Assessment (NCCHTA) (the
commissioning body) requested that the proposal
should be revised to incorporate a competitive bid
which also included three centres, namely
Papworth, London and Leeds, and to shorten the
recruitment period to 1 year. London was
recruited to the trial after a delay of a few months.
Discussions with Papworth and Leeds continued
for some months but they eventually declined to
take part in the trial.
Recruitment period
Participants were recruited from November 1999
to December 2001. Bristol, Leicester and
Manchester started recruiting at the same time but
there were delays in setting up the trial in
London; for example, recruiting a research nurse
took 4 months and recruitment started there only
in May 2000.
Bristol and Leicester recruited participants over a
2-year period and London and Manchester
recruited for 1 year only. This difference in
recruitment period occurred because of
negotiations with the NCCHTA about continuing
the trial in view of the non-participation of
Papworth and Leeds and the slow rate of
recruitment in the other centres. After 1 year, we
proposed to focus the effort of research staff on
the two centres that were recruiting relatively well,
Bristol and Leicester, since it was difficult to justify
the investment in the research nurses in
Manchester and London given their rates of
recruitment.
Outcomes
Contrary to our intention, it was not possible to
blind data reported to the coordinating centre
about potential adverse and cardiac-related events.
The inability to blind arose because information
from centres about suspected events was not
always presented in a uniform manner and often
disclosed information about the intervention, for
example, ‘anastomosis patent’. We were faced with
two alternatives: either extract the information
from reports about suspected events so that the
information could be presented without disclosing
the intervention received or present the information
as it had been submitted by centres, accepting that
the reviewers would not be blinded. Because the
process of data extraction itself could not be
blinded, and because one reviewer was a surgeon
and one a cardiologist (i.e. representing
potentially opposing interests), we chose to
present the information as it had been submitted.
The reliability of classification of all suspected
events was described using Cohen’s   statistic.22
Evidence available for review was not always the
same for all patients suspected of having
experienced a cardiac-related event. Centres
tended to re-investigate patients suspected of
having a recurrence of angina according to their
usual practices, rather than according to the
protocol. We obtained all available information
when a participant was reinvestigated and
presented this to the cardiologist and cardiac
surgeon, who independently adjudicated possible
cardiac related events. Reviewers were allowed to
conclude that there was insufficient information to
decide whether or not an event had occurred, in
which case we requested additional information
and, if available, fed back the information to the
reviewers. A third opinion was obtained in the few
instances of disagreement.
It was also sometimes impossible to obtain an ETT
at 12 months. Some patients declined to provide
information during follow-up, including having an
ETT. Because recruitment continued to within 
6 months of the end of data collection, the last
recruited patients had also not reached 
12 months’ follow-up.
Further discussion of the most appropriate
outcomes for the trial led us to substitute the
Short Form with 36 Items (SF-36)25 for the Well-
being Index as our chosen measure of generic
QoL. We also included a newly developed
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Chapter 3
Deviations from the protocolquestionnaire, the Coronary Revascularisation
Outcome Questionnaire (CROQ),26,27 as a measure
of disease-specific QoL. The CROQ was developed
to provide an instrument for assessing the
outcome of both PTCA and CABG interventions
for coronary revascularisation. It includes items
from the SF-36 and the SAQ but also includes
other questions covering cognitive and
psychological domains. The CROQ has been
evaluated and validated for patients undergoing
PTCA and CABG but not for patients undergoing
MIDCAB.
Sample size and statistical
analyses
AMIST recruited a much smaller than expected
sample size, partly because some centres withdrew
and partly because recruitment was slower than
expected even in centres that recruited relatively
well. The small sample size impacted on the
proposed analyses in two ways:
1. At the outset, we proposed to investigate
whether effectiveness depended on the date
when a procedure was carried out, since PTCA
and MIDCAB techniques might have altered
during the course of the study. This subgroup
analysis was not carried out.
2. We recruited both randomised and non-
randomised participants to AMIST. We had
planned to carry out a comprehensive cohort
analysis,28 assuming that we might have similar
numbers of randomised and non-randomised
patients, to compare the estimates of
effectiveness in the two cohorts. The small
number of non-randomised participants 
(n = 27, about one-quarter of the number of
randomised participants) and the fact that
almost all non-randomised participants
underwent PTCA (25/27) made this analysis
impracticable. Instead, for the primary
outcome only, we simply carried out an
explanatory (observational) analysis according
to the treatment received, including all
participants who received one or other
intervention. Four patients, one who died
before receiving the assigned intervention, two
who received medical treatment only and one
who underwent planned CABG as the initial
procedure, were excluded from this explanatory
analysis.
Research governance
After the first meeting, the DMC received
information and communicated electronically. 
An interim analysis was not carried out because
the sample size never reached half of the 
planned target of 360, that is, any interim analysis
would have had very little power to detect a
difference. 
Deviations from the protocol
12Recruitment and assignment to
interventions
Participants were recruited from November 1999
to December 2001. Bristol and Leicester recruited
over 2 years and Manchester (November 1999 to
October 2000) and London (April 2000 to March
2001) recruited over only 1 year. During these
periods of recruitment, the details of 12,828
consecutive patients undergoing a diagnostic
angiogram or elective PTCA were logged. A total
of 1091 patients (8.5%) were identified as
potentially suitable for the trial (Figure 1), that is
they were believed to have proximal stenosis of the
LAD only. 
The first 100 patients (out of 961; data for both
reviewers available for 94) considered for the trial
were evaluated independently by a cardiologist
and a surgeon to test the reliability of the
application of the eligibility criteria. The  
estimates were derived first for the decision about
whether a patient was eligible or not and, second,
for classification of patients in five categories
(eligible; not eligible because of compromising a
side-branch; not eligible because lesion too close
to the left main stem; not eligible because the
degree of stenosis was <50%; not eligible for
another reason). The   estimates were excellent in
both cases, namely 0.75 (p < 0.0001) and 0.77 
(p < 0.0001). The decisions of the reviewers are
shown in Table 4.
Of the patients regarded as potentially suitable,
794 did not satisfy the eligibility criteria and 130
were not approached; reasons for being ineligible
or not being approached are described in Table 5.
Of the remaining 167 eligible patients, 40 did not
consent to participate at all (24.0%). Recruitment
figures by centre are shown in Appendix 1 and
reasons for refusing to participate in Appendix 2.
A total of 100 participants were randomised, 
50 to PTCA and 50 to MIDCAB. The baseline
characteristics of the participants in the two
groups are summarised in Tables 6 and 7. There
were no serious imbalances in characteristics
between groups. Six randomised participants did
not receive the assigned interventions. Of the 48
patients who underwent PTCA, only one did not
receive a stent. The remaining 27 participants
agreed to follow-up but declined to be
randomised; 25 preferred and underwent PTCA,
one preferred and underwent MIDCAB and one
underwent conventional CABG. A flow chart for
the trial is shown in Figure 1. Adherence to other
CONSORT criteria29 are described in Appendix 3. 
Prior to receiving the intervention, diagnoses for
2/100 (2%) randomised participants were reviewed
following a second angiogram and were judged to
be different compared with the initial assessment
and the revised diagnoses were no longer
consistent with the eligibility criteria. Both
participants were in the PTCA group. One was
found to have insufficiently severe disease at the
time of the planned index procedure, did not
proceed to have PTCA and was given medical
treatment. The other was found not to have a
sufficiently severe LAD lesion on review of the
angiogram and was given medical treatment. A
third patient who elected to undergo MIDCAB but
who consented to follow-up was found to have
double-vessel disease and was given CABG. These
patients were included in the analyses since they
were initially considered to satisfy the eligibility
criteria.
Time to intervention
Differential time spent waiting for the intervention
is often a concern in randomised controlled trials
that compare surgical and medical treatments.
Although PTCA involves a procedure, we were
similarly concerned that the waiting time for
PTCA might be shorter than for MIDCAB despite
the intention to provide both interventions to all
patients with 1 month. We therefore compared the
time from randomisation to intervention between
groups. 
Unsurprisingly, times to intervention were highly
positively skewed. Twenty-two and 19 randomised
participants received PTCA and MIDCAB,
respectively, within 30 days. The corresponding
median times to intervention were 35 days (inter-
quartile range 6.5–54 days) and 44 days (inter-
quartile range 14–66 days). A non-parametric
rank sum test did not indicate a statistically
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Chapter 4
Resultssignificant difference between the medians 
(z = –1.339, p = 0.18). The analysis of times to
intervention revealed one participant, randomised
to PTCA, who inexplicably had a date of
intervention that preceded the date of
randomisation.
Short-term outcomes
There were no conversions to surgery (either to
MIDCAB or to CABG) among participants
randomly assigned to PTCA. There were three
conversions from MIDCAB to median sternotomy
Results
14
All registered patients undergoing angiogram/elective PTCA                        n = 12,828
Eligible patients randomised                        n = 100
Potentially eligible patientsa n = 1091 Ineligible patients
Eligible patients not approached
(see Table 1 for reasons)
n = 794
n = 130
a The majority of patients (n = 11,737) were clearly ineligible (e.g. multi-vessel disease).
b Event data were analysed for all patients using survival analysis; data for patients were censored at the last date when their 
clinical status could be confirmed.
c Patients completed monthly questionnaires detailing health and social resource use data and also QoL questionnaires at 3, 
6 and 12 months after the procedure; the information reported above for follow-up is based on all contacts with patients 
and does not necessarily imply that QoL data were available at these time points.
Eligible patients approached   n = 167 Eligible patients who did not consent 
(see Tables 2 and 3 for reasons)
n = 40
Eligible patients who consented  n = 127 Eligible patients followed-up
(see Figure 2)
n = 27
Patients who received PTCA
Reason for not receiving PTCA:
• 2 patients received medical intervention only after 
diagnostic review
n = 48 Patients who received MIDCAB
Reasons for not receiving MIDCAB:
• 1 patient died before intervention
• 3 patients received PTCA in error
n = 46
3-month follow-up
Reasons for missing follow-up data:
• 2 patients did not respond
• 2 patients refused
n = 46 3-month follow-up
Reasons for missing follow-up data:
• 4 patients did not respond
• 0 patients refused
• 2 patients deceased
n = 44
Patients randomised to PTCA n = 50 Patients randomised to MIDCAB n = 50
Follow-upb,c Follow-upb,c
6-month follow-up
Reasons for missing follow-up data:
• 5 patients did not respond
• 4 patients refused
n = 41 6-month follow-up
Reasons for missing follow-up data:
• 2 patients did not respond
• 0 patients refused
• 2 patients deceased
n = 46
12-month follow-up
Reasons for missing follow-up data:
• 2 patients did not respond
• 2 patients refused
• 8 patients had not reached 12 months
n = 38 12-month follow-up
Reasons for missing follow-up data:
1 patient did not respond
0 patients refused
7 patients had not reached 12 months
2 patients deceased
n = 40
FIGURE 1 Flow chart of recruitment and follow-up for AMISTamong participants randomly assigned to
MIDCAB, one of which was planned before
starting the operation because of the patient’s
body structure. The non-randomised patient who
underwent conventional CABG did not represent
a conversion since he was found to have double-
vessel disease on review, received two grafts and
there was no record of an incision for a
thoracotomy having been made initially.
Table 8 summarises the frequencies of
complications/adverse events that occurred in
hospital. No major adverse events occurred. 
Table 9 summarises the duration of length of stay
overall, in recovery and in intensive care. Not
surprisingly, there were statistically significant
differences between the medians for the two
groups with respect to total, postprocedure and
intensive care length of stay (all p < 0.0001).
Duration of follow-up
For randomised patients, 12-month follow-up was
complete for 84/100 (84%) patients. The median
follow-up for cardiac-related events was 20.5 months
(inter-quartile range 14.8–24.2 months). For those
who refused randomisation, 22/27 (81%)
completed 12-month follow-up and the median
follow-up for cardiac-related events was 20.9 months
(inter-quartile range 15.0–22.4 months). There was
no difference in the duration of follow-up between
groups for randomised patients (difference in
mean follow-up (MIDCAB – PTCA) = 0.3 months,
95% CI –2.5 to 3.0, p = 0.84). Duration of follow-
up for non-randomised patients was not compared
between groups because there was only one who
underwent MIDCAB.
Survival free from cardiac-related
events
Reliability of classification of 
cardiac-related events
Table 10 shows the classifications of suspected
cardiac-related events by the independent
cardiologist and cardiac surgeon. The reliability of
classification was moderate (  = 0.59). Reliability
appears worse than it really was because some
disagreements were easily reconciled. The three
misclassified but confirmed events related to: 
  One patient whose ETT showed evidence of an
MI; the disagreement arose because the cardiac
surgeon wanted confirmation that the ECG
changes had not been present at the time the
patient was recruited.
  One patient who definitely had recurrent
angina; the disagreement arose because
angiography showed a lesion in a different
vessel.
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TABLE 4 Agreement between independent reviewers (one cardiologist and one cardiac surgeon) in applying the eligibility criteria: 
(a) with respect to overall eligibility and (b) with respect to five main classification categories
(a)
Decision of cardiac surgeon Total
Decision of cardiologist Not eligible Eligible
Not eligible 80 3 83
Eligible 2 9 11
Total 82 12 94
  = 0.75, p < 0.0001.
(b)
Decision of cardiac surgeon Total
Decision of cardiologist (i) (ii) (iii) (iv) (v)
(i) Not eligible – lesion compromises side branch 26 0 0 6 1 33
(ii) Not eligible – lesion too close to left main stent (LMS) 0 8 1 1 0 10
(iii) Not eligible – stenosis <50% 0 0 14 1 0 15
(iv) Not eligible – other reason 0 0 2 21 2 25
(v) Eligible 0 0 1 1 9 11
Total 26 8 18 30 12 94
  = 0.77, p < 0.0001.R
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TABLE 5 Reasons for excluding patients from AMIST
Reason (excluding patient refusals) Bristol  Leicester  London  Manchester  Total 
(n = 146) (n = 461) (n = 203) (n = 114) (n = 924)
Aortic/mitral regurgitation, III–IV 2 8 2 12 (1%)
Bleeding diathesis 1 1 2 4 (0%)
Blocked LAD 26 109 7 26 168 (18%)
Body mass index ≥35 (severe obesity) 2 6 2 10 (1%)
Bullous emphysema  2 1 3 (0%)
Disease not severe enough for intervention 16 6 22 (2%)
Doctor refused or forgot AMIST 2 33 62 3 100 (11%)
Doctor refused, took patient off waiting list 26 2 28 (3%)
Emergency case 5 19 3 11 38 (4%)
Previous cardiac historya 3 5 2 10 (1%)
Lesion involved side branch 36 28 3 22 89 (11%)
Left ventricular impairment (ejection fraction <30%) 2 7 1 1 11 (1%)
Lesion was in the distal part of the LAD 6 11 11 5 33 (3%)
Lesion not 50% of diameter stenosis 12 81 25 12 130 (13%) 
No ischaemia 2 9 3 9 23 (2%)
Disease in other major coronary vessels 1 18 19 (2%)
Previous CABG 1 4 7 1 13 (1%)
Previous MI 13 7 34 4 58 (6%)
Previous PTCA/stent 8 36 12 2 58 (6%)
Patient in another study 5 1 6 (1%)
Patient unable to comply 2 2 (0%)
Patient unable to speak English 1 2 3 (0%)
Significant stenotic valve disease 1 6 2 9 (1%)
Surgeon/surgical bed unavailable 8 8 (1%)
Symptomatic cerebrovascular disease 2 3 5 (1%)
Too close to the left main stem 11 11 3 2 27 (3%)
Thrombus 1 2 3 (0%)
Unsuitable for PTCA/MIDCAB 7 11 2 3 23 (2%)
Other, e.g. aneurysmb 1 7 1 9 (1%)
a Pericarditis/median sternotomy/thoracotomy/chest irradiation/pleurodesis.
b Bristol, uncontrolled diabetes; Leicester, missed cases (2), lesion long/complex (3), patient too young (1), aneurysm (1); Manchester, referred to another hospital.Health Technology Assessment 2004; Vol. 8: No. 16
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TABLE 6 Baseline demographic and clinical characteristics of PTCA and MIDCAB groups
PTCA (n = 50)a MIDCAB (n = 50)b
Baseline characteristic n/median %/IQR n/median %/IQR
Age (years) 54.5 48.9–61.4 58.8 53.2–66.6
Female 7 14 15 30
Non-Caucasian 2 4 1 2
Employment status:a
Full-time or part-time work 22 49 19 40
Home-maker 4 9 1 2
Retired 11 24 22 46
Disabled 5 11 3 6
Unemployed 3 7 3 6
New York Heart Association class:b
16 1 4 7 1 4
2 2 04 5 3 57 0
31 6 3 6 7 1 4
42 5 1 2
Unstable anginac 92 0 1 02 0
Degree of stenosis of LAD:d
≥50% and <80% 7 15 11 23
≥80% and <90% 9 20 11 23
≥90% and <95% 15 33 12 25
≥95% 15 33 14 29
a Missing for five PTCA and two MIDCAB participants.
b Missing for six PTCA participants.
c Missing for five PTCA and one MIDCAB participants.
d Missing for four PTCA and two MIDCAB participants.
TABLE 7 Baseline functional and quality of life characteristics of PTCA and MIDCAB groups
PTCA (n = 50) MIDCAB (n = 50)
Baseline characteristic Median SD Median SD
SAQ:a
Physical limitation 56.1 21.7 57.7 20.2
Angina stability 42.6 28.0 32.8 28.3
Angina frequency 51.6 25.2 53.6 25.5
Treatment satisfaction 87.5 13.1 87.8 14.1
Disease perception 41.7 20.6 40.1 16.5
CROQ:b
Core total 50.1 5.4 50.7 5.8
Symptoms 56.2 23.6 56.6 23.3
Physical 59.3 27.4 60.6 25.8
Cognitive 76.5 23.2 73.6 26.2
Psychological 62.5 19.4 66.3 18.1
SF-36:c
PCS 29.5 12.7 28.9 13.6
MCS 44.2 9.9 46.1 11.4
EuroQol:d
Utility score 0.66 0.26 0.72 0.22
Health status score 57.3 19.8 64.4 17.4
a Scores could not be calculated because of missing data for six PTCA and five MIDCAB participants.
b Scores could not be calculated because of missing data for two PTCA and four MIDCAB participants.
c Scores could not be calculated because of missing data for five PTCA and eight MIDCAB participants.
d Scores could not be calculated because of missing data for two PTCA and three MIDCAB participants.Results
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TABLE 8 Short-term complications/adverse events in PTCA and MIDCAB groups
PTCA (n = 49)a MIDCAB (n = 49)b
Decision of cardiologist n % n %
Death in hospital 0 0 0 0
Conversion to surgery/sternotomy 0 0 3 6
Myocardial infarction 0 0 0 0
Ventricular fibrillation 0 0 1 2
Bleeding femoral puncture 5 10 0 0
Arrhythmia 0 0 4 8
Postprocedure persistent angina 1 2 0 0
Postprocedure taken to operating theatre:
Because of bleeding 0 0 1 2
Because of infection 0 0 0 0
Because of sternotomy 0 0 0 0
Transfusion requirement (patients):
Blood 0 0 1 2
Platelets 1 2 1 2
Fresh frozen plasma 0 0 1 2
Wound infection 1 2 3 6
Wound inflammation 1 2 0 0
Pericarditis 0 0 2 4
a One patient assigned to PTCA is excluded because the patient was treated medically and never received a date for PTCA.
A second patient, who attended for PTCA and underwent an angiogram but who did not undergo PTCA because the
degree of stenosis of the lesion was judged to be <50% at the time of the planned intervention, is included. 
b One patient assigned to MIDCAB is excluded because the patient died at home before undergoing the planned operation. 
TABLE 9 Length of stay and use of blood products in PTCA and MIDCAB groups
PTCA (n = 49)a MIDCAB (n = 49)b
Decision of cardiologist Median IQRc Median IQRc
Total stay (days) 2 1–36 5 –8
Postprocedure stay (days) 1 1–14 4 –5
Time in recovery (hours) 0 0–0.83 0 0–1
Time in intensive care unit (hours) 0 0–05 0 –20
a One patient assigned to PTCA is excluded because the patient was treated medically and never received a date for PTCA.
A second patient, who attended for PTCA and underwent an angiogram but who did not undergo PTCA because the
degree of stenosis of the lesion was judged to be <50% at the time of the planned intervention, is included. 
b One patient assigned to MIDCAB is excluded because the patient died at home before undergoing the planned operation. 
c IQR, inter-quartile range. 
TABLE 10 Agreement between independent reviewers (one cardiologist and one cardiac surgeon) in classifying non-fatal suspected
eventsa
Decision of cardiac surgeon Total
Decision of cardiologist No event Event Uncertain
No event 12 (0) 3 (2) 3 (0) 18 (2)
Event 1 (1) 13 (13) 0 (0) 14 (14)
Uncertain 2 (0) 0 (0) 2 (0) 4 (0)
Total 15 (1) 16 (15) 5 (0) 36 (16)
  = 0.59, p < 0.0001.
a Numbers in parentheses represent suspected events that were confirmed as cardiac-related events, i.e. there were 16
non-fatal cardiac-related events in total.  One patient whose ETT was limited in
duration; the disagreement arose because of
differing interpretation of the extent to which
exercise was limited. The cardiologist
responsible confirmed that the ETT was
positive and additional anti-angina drugs were
prescribed.
The two patients about whom both reviewers were
uncertain were classified as agreements because
both reviewers agreed that the patients had
experienced an episode of pericarditis and were
uncertain only about whether pericarditis should
be classified as a cardiac-related event. Pericarditis
was not included in our definition of cardiac-
related events and these two patients are included
in Table 8.
Primary, intention-to-treat analysis
All randomised participants were included in the
primary analysis of survival free from cardiac-
related events. Table 11 shows the frequencies of
events that occurred during follow-up, without
taking into account time that had elapsed since
the procedure. The table distinguishes 
re-intervention, symptomatic recurrent angina that
caused participants to seek re-investigation and
participants found to have evidence of ischaemia
from the results of the 12-month ETT (exercise
duration limited by the onset of chest pain or an
ST depression >1 mm). In practice, the distinction
between these categories may be artificial, arising
more from access to, or the availability of, hospital
resources (e.g. re-intervention versus symptomatic
recurrent angina; information on the latter
patients sometimes indicated that re-intervention
was planned or scheduled) or from the symptom
threshold of patients (e.g. symptomatic recurrent
angina versus evidence of ischaemia from the ETT
at 12 months) than from true differences in the
types of events experienced.
Figure 2 shows the inverted Kaplan–Meier curves
for survival free from cardiac-related events for the
PTCA and MIDCAB groups. Table 12 shows the
observed cumulative percentage experiencing
events after different durations of follow-up. 
The survival analysis for MIDCAB versus PTCA
found a non-significant benefit from MIDCAB
(hazard ratio = 0.77, 95% CI 0.38 to 1.57, 
p = 0.47). The proportional hazards assumption
was satisfied ( 2 = 0.00, p = 1.00). The estimated
cumulative percentages experiencing events 
at 1 year for PTCA and MIDCAB groups 
from the survival model were 9.2 and 7.1%,
respectively.
Secondary, explanatory analysis
All participants who underwent PTCA or 
MIDCAB were included in a secondary analysis 
of survival free from cardiac-related events,
excluding two patients assigned to PTCA 
who did not receive any intervention, one 
patient assigned to MIDCAB who died before
receiving any intervention and one patient who
elected to have surgery and who underwent
CABG. Table 13 shows the frequencies of events
that occurred during follow-up, without taking
into account time that had elapsed since the
procedure (cf. Table 10).
Figure 3 shows the inverted Kaplan–Meier curves
for survival free from cardiac-related events for the
PTCA and MIDCAB groups, as estimated by the
explanatory analysis. As with intention-to-treat
analysis, the explanatory analysis found a non-
significant benefit from MIDCAB (hazard ratio 
= 0.70, 95% CI 0.36 to 1.38, p = 0.31). The
proportional hazards assumption was satisfied 
( 2 = 0.08, p = 0.78). The estimated cumulative
percentages experiencing events at 1 year for
PTCA and MIDCAB groups from the survival
model were 7.4 and 5.2%, respectively.
Health Technology Assessment 2004; Vol. 8: No. 16
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TABLE 11 Randomised participants experiencing cardiac-related events during follow-up (ITT analysis; median follow-up 
20.5 months)
PTCA (n = 50) MIDCAB (n = 50)
Event n (%) n (%)
Death 0 (0) 2 (4)
MI 2 (4) 0 (0)
Re-intervention 2 (4) 0 (0)
Recurrent angina 5 (10) 4 (8)
Evidence of ischaemia at 12-month ETT 8 (16) 8 (16)
Total 17 (34) 14 (28)Results
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FIGURE 2 Inverted Kaplan–Meier survival curves for PTCA and MIDCAB groups, ITT analysis
TABLE 12 ITT analysis: numbers at risk of experiencing cardiac-related events, and observed cumulative percentages experiencing an
event, for PTCA and MIDCAB participants with increasing duration of follow-up
Follow-up duration (months) Number at risk Cumulative % 95% CI
PTCA:
6 49 4.0 0.010 to 0.151
12 44 8.1 0.031 to 0.201
18 30 18.3 0.095 to 0.337
24 14 44.5 0.330 to 0.642
MIDCAB:
6 49 4.0 0.010 to 0.151
12 42 8.2 0.032 to 0.201
18 31 13.0 0.060 to 0.267
24 16 27.6 0.152 to 0.469
TABLE 13 All participants experiencing cardiac-related events during follow-up (explanatory analysis)
PTCA (n = 76) MIDCAB (n = 47)
Event n (%) n (%)
Death 0 (0) 1 (2)
MI 2 (3) 0 (0)
Re-intervention 2 (3) 0 (0)
Recurrent angina 8 (11) 4 (8)
Evidence of ischaemia at 12-month ETT 13 (17) 7 (17)
Total 25 (32) 12 (27)Functional ability, symptoms 
and disease-specific quality 
of life
The results for the SAQ and the CROQ [means
and standard deviations (SDs) for each group,
mean difference and 95% CI] are shown in 
Tables 15 and 16. Differences were estimated 
from regression analyses that adjusted for the
participants’ baseline scores. Therefore, 
the tabulated mean differences are not 
equal to the differences between the tabulated
means. 
For both measures, differences tended to favour
MIDCAB although only two differences reached
statistical significance (SAQ treatment satisfaction
score at 3 months, p = 0.02; CROQ cognitive
score at 3 months, p = 0.04). SAQ dimensions of
angina stability and frequency and CROQ physical
and cognitive dimensions (especially at 3 months)
suggested the most consistent benefit of MIDCAB
but the differences were still statistically non-
significant. Given the large number of
comparisons carried out (5 + 6 dimensions/scores
at three different time points), one should
interpret the one or two statistically significant
results with caution.
Health Technology Assessment 2004; Vol. 8: No. 16
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FIGURE 3 Inverted Kaplan–Meier survival curves for PTCA and MIDCAB groups, explanatory analysis
TABLE 14 Explanatory analysis: numbers at risk of experiencing cardiac-related events, and observed cumulative percentages
experiencing an event, for PTCA and MIDCAB participants with increasing duration of follow-up
Follow-up duration (months) Number at risk Cumulative % 95% CI
PTCA:
6 75 2.6 0.007 to 0.100
12 66 6.6 0.028 to 0.152
18 45 15.0 0.083 to 0.264
24 15 49.6 0.350 to 0.663
MIDCAB:
6 47 2.1 0.003 to 0.139
12 41 6.5 0.021 to 0.187
18 30 13.7 0.064 to 0.280
24 16 23.8 0.129 to 0.415R
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TABLE 15 SAQ scores at 3, 6 and 12 months for PTCA and MIDCAB groups, and differences between groups
PTCA MIDCAB PTCA vs MIDCABa
n Mean SD n Mean SD Difference 95% CI p
Physical limitation: 
At 3 months 43 77.9 22.5 43 80.1 20.5 3.59 –4.78 to 12.0 0.40
At 6 months 39 76.3 24.8 46 78.6 20.3 2.62 –6.36 to 11.6 0.56
At 12 months 35 80.4 24.6 38 81.0 21.4 2.99 –6.95 to 12.9 0.55
Angina stability: 
At 3 months 45 72.8 31.0 42 82.1 24.2 11.3 –0.96 to 23.5 0.07
At 6 months 40 66.3 29.7 44 70.5 29.2 8.03 –4.34 to 20.4 0.20
At 12 months 36 64.6 28.3 36 66.7 29.9 2.31 –12.0 to 16.6 0.75
Angina frequency:
At 3 months 45 76.4 27.4 43 84.9 19.4 8.48 –1.45 to 18.4 0.09
At 6 months 38 76.6 29.4 44 84.3 20.6 6.49 –4.49 to 17.5 0.24
At 12 months 30 80.0 24.4 38 86.3 21.4 7.23 –4.14 to 18.6 0.21
Treatment satisfaction: 
At 3 months 45 87.5 14.7 43 92.3 11.9 5.70 0.78 to 10.6 0.02
At 6 months 38 86.8 16.0 45 86.4 19.1 –0.15 –7.26 to 6.96 0.97
At 12 months 35 81.3 25.1 37 84.1 23.1 2.41 –8.98 to 13.8 0.68
Disease perception: 
At 3 months 46 68.9 23.3 43 72.3 22.9 4.66 –4.58 to 13.9 0.32
At 6 months 40 68.1 23.7 45 68.0 23.4 0.61 –9.03 to 10.2 0.90
At 12 months 35 72.6 25.2 37 71.5 23.5 –0.04 –11.8 to 11.7 1.00
a Mean differences between groups at each time point were estimated using regression, adjusting for participants’ baseline scores (see Table 7). Therefore, the tabulated differences
are not equal to the differences between the tabulated means.H
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TABLE 16 CROQ scores at 3, 6 and 12 months for PTCA and MIDCAB groups, and differences between groups
PTCA MIDCAB PTCA vs MIDCABa
n Mean SD n Mean SD Difference 95% CI p
Core total:b
At 3 months 44 49.7 7.09 44 50.0 6.40 –0.19 –2.54 to 2.15 0.87
At 6 months 39 50.3 7.52 46 50.0 6.45 –0.99 –3.59 to 1.61 0.45
At 12 months 35 50.4 8.00 39 50.1 7.34 –0.67 –4.13 to 2.79 0.70
Symptoms: 
At 3 months 44 77.6 24.2 44 85.8 16.8 6.95 –0.39 to 14.3 0.06
At 6 months 38 78.7 22.9 46 84.0 18.7 4.28 –3.67 to 12.2 0.29
At 12 months 35 82.2 22.8 39 83.7 21.9 –0.16 –9.92 to 9.60 0.97
Physical: 
At 3 months 44 80.3 25.6 43 86.2 20.3 5.86 –2.83 to 14.6 0.18
At 6 months 39 79.7 26.9 46 82.1 20.5 1.76 –7.62 to 11.1 0.71
At 12 months 35 82.2 27.3 39 83.3 22.9 0.99 –10.0 to 12.0 0.86
Cognitive: 
At 3 months 44 80.0 20.4 44 85.8 21.5 7.65 0.44 to 14.9 0.04
At 6 months 39 82.9 19.6 45 82.4 22.0 2.11 –6.21 to 10.4 0.61
At 12 months 35 82.9 21.2 39 82.7 24.9 1.19 –9.19 to 11.6 0.82
Psychology: 
At 3 months 44 77.5 19.2 44 82.4 16.5 2.41 –4.01 to 8.83 0.46
At 6 months 39 79.2 20.9 45 81.2 17.1 –0.30 –7.42 to 6.82 0.93
At 12 months 35 82.1 22.1 39 84.4 18.9 2.05 –7.27 to 11.4 0.66
Satisfaction: 
At 3 months 43 84.3 16.8 44 81.4 20.9 –2.89 –10.9 to 5.20 0.48
At 6 months 38 83.8 20.2 45 79.7 22.1 –4.11 –13.4 to 5.22 0.38
At 12 months 35 80.3 21.5 38 84.9 20.2 4.61 –5.13 to 14.3 0.35
a Mean differences between groups at each time point were estimated using regression, adjusting for participants’ baseline scores (see Table 7). Therefore, the tabulated differences
are not equal to the differences between the tabulated means.
b CROQ core total dimension is a T-score, i.e. the dimension is scored on a scale with a mean of 50 and a SD of 10.Generic quality of life
The results for the SF-36 and the EuroQol (means
and SDs for each group, mean difference and 95%
CI) are shown in Table 17. Differences were
estimated from regression analyses that adjusted
for the participants’ baseline scores. 
For both measures, differences again tended to
favour MIDCAB although the differences were very
small and only one reached statistical significance
(SF-36 MCS score at 12 months, p = 0.04). As for
the SAQ and CROQ, given the number of
comparisons carried out, this statistically significant
result should be interpreted with caution.
Economic evaluation
Costs of PTCA and MIDCAB
The costs profiles of the two procedures differed
markedly (see Table 18). MIDCAB had high costs
of ward stay both before and after the procedures,
with an average length of stay of 5 days after the
operation and 7 days in total compared with 
1.4 days for PCTA after the procedure and 
2.7 days in total. The costs of these components
were £1120 per patient for MIDCAB after the
procedure and £1586 in total, and £162 per
patient for PCTA after the procedure and £310 in
total. (Since patients were randomised to PTCA
and MIDCAB, there is no reason for the ward
costs before the procedure to differ between
groups. Therefore, only the ward costs after the
procedure are included in the following analyses.)
Not only was the length of stay longer but also the
cost per day was higher, reflecting more intensive
care required postoperatively. The MIDCAB cases
spent an average of 25 hours in ITU but no PCTA
cases were admitted to ITU. The MIDCAB cases
also spent more time in recovery (32 hours in total
compared with 22 hours for PCTA cases). 
There were considerable consumables and
equipment used in PCTA that amounted to £538
but the staff costs in operating theatre/catheter
laboratory were greater for the MIDCAB at £478
compared with £143 for PCTA. Drug costs during
admission and at discharge were slightly higher
for PCTA; the medicines prescribed on discharge
were significantly different (p < 0.001). The costs
of medications during follow-up were also slightly
higher for the PCTA group. This seems consistent
with clinical experience of prescribing for this
group. Follow-up costs that included consultations
at home and in surgeries and telephone calls for
advice were higher for MIDCAB than for PCTA.
Use of hospital facilities during follow-up was also
higher for MIDCAB than for PCTA.
Furthermore, MIDCAB patients had to take a
mean 2.5 days more off work. Therefore, patient
costs in the reference population were also highest
in the MIDCAB group. 
Cost-effectiveness of MIDCAB
The utility values (derived using EuroQol) at 
12 months are based on the values recorded at
that time and are summarised in Table 17. The
differences between the groups were not
statistically significant after 12 months’ follow-up.
The mean 12-month utility scores are shown again
in Table 19, together with the total NHS costs of
PTCA and MIDCAB and the incremental
cost–utility ratio for MIDCAB, which is £44,600
per (EuroQol) quality-adjusted life year (QALY). 
If patient costs are included, the incremental
cost–utility ratio rises to £58,724 per (EuroQol)
QALY. (Alternatively, the health status profile over
the 12 months could have been calculated using a
weighted average of the utility at 3, 6 and 12
months. However, the weighted 12-month utility
gave mean values that were almost identical with
those observed at the 12-month follow-up and the
estimated difference between groups, adjusted for
baseline utility scores, was 0.01.) 
Sensitivity analysis
Sensitivity analysis of the costs of PTCA and
MIDCAB, as described in ‘Economic evaluation’
(see p. 9), is shown in Table 20. The costs of PCTA
were 67% (£1789/£2681) of those for MIDCAB.
The key component of this difference in costs
relates to ward costs; for PCTA these were only
14% (£162/£1120) of the MIDCAB costs. Most of
the difference in ward costs related to length of
stay. A decrease in MIDCAB length of stay by 80%
would have been needed to achieve equivalence in
cost of length of stay between the procedures. 
For one MIDCAB one could produce 1.4 PTCAs.
There is some discussion in the literature about
the possibility of the two procedures breaking even
after 5 years because of the greater propensity for
patients who undergo PTCA to require a repeat
revascularisation procedure (either PTCA or
CABG). The long-term cost-effectiveness could be
modelled once reliable data on long term
outcomes become available. Data already
published30,31 suggest that the rates of cardiac-
related events observed in AMIST (and
consequent resource use and costs during 
follow-up) may not be typical (see ‘Findings of the
study in the context of existing literature’, p. 29).
Results
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TABLE 17 SF-36 T scores (physical and mental health dimensions, PCS and MCS, respectively)a and EuroQol/EQ5D utility and health status scores at 3, 6 and 12 months for PTCA and MIDCAB
groups, and differences between groups
PTCA MIDCAB PTCA vs MIDCABb
n Mean SD n Mean SD Difference 95% CI p
SF-36 PCS: 
At 3 months 43 37.9 14.3 43 40.9 11.5 1.57 –3.40 to 6.54 0.53
At 6 months 41 37.4 15.9 45 38.0 10.8 0.01 –5.14 to 5.15 1.00
At 12 months 38 37.7 15.0 38 39.4 14.4 0.63 –5.47 to 7.03 0.80
SF-36 MCS: 
At 3 months 43 50.5 12.2 43 51.5 9.55 0.07 –4.28 to 4.42 0.98
At 6 months 41 51.1 11.2 45 52.4 10.1 1.76 –2.26 to 5.77 0.39
At 12 months 38 51.4 11.6 38 55.0 9.18 4.80 0.34 to 9.27 0.04
EQ5D utility: 
At 3 months 43 0.79 0.24 41 0.84 0.14 0.02 –0.06 to 0.10 0.60
At 6 months 39 0.78 0.24 43 0.80 0.19 –0.01 –0.10 to 0.08 0.79
At 12 months 38 0.77 0.25 40 0.82 0.22 0.02 –0.08 to 0.12 0.71
EQ5D health status: 
At 3 months 45 72.4 18.3 44 79.8 17.4 4.28 –1.94 to 10.5 0.18
At 6 months 40 74.3 20.0 46 79.7 13.8 1.07 –5.15 to 7.29 0.73
At 12 months 38 74.6 21.7 40 81.7 12.7 3.19 –4.75 to 11.1 0.43
a Quality of life dimension scored on a scale with a mean of 50 and a SD of 10.  T scores are also normalised for the SF-36 component summaries (PCS and MCS; i.e. 50 represents
the mean for a normal population).
b Mean differences between groups at each time point were estimated using regression, adjusting for participants’ baseline scores (see Table 7). Therefore, the tabulated differences
are not equal to the differences between the tabulated means.Results
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TABLE 18 Component costs per patient (£) for PTCA and MIDCAB
Procedure costs PTCA MIDCAB Ratio  Ratio 
(PCTA/MIDCAB) (MIDCAB/PCTA)
Hospital costs for index procedure
Ward costs (total) 310 1586 0.20 5.12
Ward costs (postop.) 162 1120 0.14 6.91
Medication inpatient 39.8 13.4 2.97 0.34
Medication on discharge 63 37 1.70 0.59
Total medications 102.8 50.4 2.04 0.49
Procedure costs: staff 143 478 0.30 3.34
Procedure costs: equipment 538
Total procedure costs  681 478 1.42 0.70
Total hospital costs  1093.8 2114.4 0.52 1.93
Total hospital costs postprocedure 945.8 1648.4 0.57 1.74
Hospital cost of follow-up
Use of hospital call services  4.82 23.51 0.21 4.88
Outpatient consultations: consultants and  51.7 43.1 1.20 0.83
other professionals
Accident and emergency attendances 7.84 9.64 0.81 1.23
Readmissions 297.03 393.5 0.75 1.32
Home visits by hospital staff 7.41 57.64 0.13 7.78
Total follow-up costs to hospital 368.8 527.39 0.70 1.43
Primary care
Consultation with GP in surgery  199.13 266.43 0.75 1.34
Consultations with GP at home 5.12 13.49 0.38 2.63
Medications during follow-up 236 196 1.20 0.83
Consultations/calls to surgery  34.26 29.26 1.17 0.85
Total follow-up costs to primary care  474.51 505.18 0.94 1.06
Patients’ costs 
Travel 2.76 2.2 1.25 0.80
Out-of-pocket expenses 5.46 4.82 1.13 0.88
Total patient costs during follow-up 8.22 7.02 1.17 0.85
Value of time off work
Patients 1204.6 1498.1 0.80 1.24
Carers 41.19 32.36 1.27 0.79
Total costs of time off work 1262.23 1544.5 0.82 1.22
TABLE 19 Estimation of incremental cost–utility for MIDCAB
Total cost 12-month  Incremental cost Incremental  Incremental 
(£) utility (£) effect cost–utility ratio (£)
PTCA 1789 0.77 n/a
MIDCAB 2681 0.82 892 0.02 44,600H
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TABLE 20 Sensitivity analysis for costs of PTCA and MIDCAB
PCTA MIDCAB PCTA MIDCAB PCTA MIDCAB PCTA MIDCAB PCTA MIDCAB
Procedure costs minus est.   0.50 est.   0.90 est.   0.90 estimate estimate est.   1.10 est.   1.10 est.   1.50 plus
est.   0.50 est.   1.50
Hospital
Ward costs (total) 155.00 793.00 279.00 1427.40 310.00 1586.00 341.00 1744.60 465.00 2379.00
Ward costs (postop.) 81.00 560.00 145.80 1008.00 162.00 1120.00 178.20 1232.00 243.00 1680.00
Medications 51.40 25.20 92.52 45.36 102.80 50.40 113.08 55.44 154.20 75.60
Procedure costs 340.50 239.00 612.90 430.20 681.00 478.00 749.10 525.80 1021.50 717.00
Total hospital costs  546.90 1057.20 984.42 1902.96 1093.80 2114.40 1203.18 2325.84 1640.70 3171.60
Total postprocedure costs  472.90 824.20 851.22 1483.56 945.80 1648.40 1040.38 1813.24 1418.70 2472.60
Follow-up costs
Hospital follow-up 184.40 263.70 331.92 474.65 368.80 527.39 405.68 580.13 553.20 791.09
Medications during follow-up 118.00 98.00 212.40 176.40 236.00 196.00 259.60 215.60 354.00 294.00
Primary care 119.26 154.59 214.66 278.26 238.51 309.18 262.36 340.10 357.77 463.77
Total NHS costs
Total healthcare costs  968.555 1573.49 1743.4 2832.27 1937.11 3146.97 2130.82 3461.67 2905.67 4720.46
Total postprocedure costs  894.555 1340.49 1610.2 2412.87 1789.11 2680.97 1968.02 2949.07 2683.67 4021.46
Patients’ costs
Value patients’ time 602.30 749.05 1084.14 1348.29 1204.60 1498.10 1325.06 1647.91 1806.90 2247.15
Value carers’ time 20.60 16.18 37.07 29.12 41.19 32.36 45.31 35.60 61.79 48.54
The bold columns show the ‘best estimate’ costs as found in the economic evaluation.Summary of main findings
Recruitment to AMIST was much slower than
expected and achieved only about 30% of the
target sample size, partly because some centres
withdrew. The trial therefore had far lower power
than desired to detect the target difference in the
frequency of cardiac-related events of 10% and all
comparisons between PTCA and MIDCAB are
imprecise. In terms of the proportion of eligible
patients recruited and the multi-centre nature of
the trial, we believe that the findings of the trial
should be applicable to the reference population. 
Survival analyses of the primary outcome (survival
free from cardiac-related events) suggested a
modest, but non-significant, benefit of MIDCAB.
The hazard ratio decreased slightly, indicating
greater benefit, in a secondary explanatory (non-
randomised) analysis. Functional and QoL scores
also suggested a slight benefit of MIDCAB,
insomuch as the comparisons consistently
favoured MIDCAB, although the size of the
differences was small and almost always non-
significant.
Compliance with the assigned intervention was
reasonably good for randomised patients. There
were no serious complications arising from either
treatment and the only deaths that occurred in the
study were unrelated to the interventions.
The economic evaluation suggests that PTCA is
more cost-effective than MIDCAB in the treatment
of proximal stenosis of the LAD provided that
there is no evidence in the future, from longer
term follow-up or other studies, that the
additional costs of MIDCAB yield an additional
health utility.
Findings of the study in the
context of existing literature
The cardiac-related event rate of 7.1% at 1 year in
the MIDCAB group, estimated from the survival
analysis, was about the same as we expected when
we calculated the target sample size for AMIST.
However, the estimated cardiac-related event rate
for PTCA at 1 year was only 9.2%, that is, a
difference in survival free from cardiac-related
events of only 2% rather than the projected 10%.
Since AMIST started to recruit, two other small
RCTs of MIDCAB versus PTCA in patients with
stenosis of the proximal LAD have been
published, one carried out in Germany30 and the
other in Poland.31 Both found that MIDCAB
reduced the risk of cardiac-related events
compared with PTCA by an amount that just
reached statistical significance. 
Diegeler and colleagues observed event rates at 
6 months of 31.5 and 14.8% for PTCA and
MIDCAB, respectively (risk difference 16.7%, 95%
CI 5.6 to 27.7%).30 These researchers had a
potentially stricter definition of cardiac-related
events than we did, since they did not include
recurrent angina as an event but did include re-
intervention on the LAD. However, in some
countries, where re-intervention is likely to be
carried out more quickly, re-intervention and
recurrent angina may be strongly correlated. We
have no explanation for their very much higher
event rates.
Cisowski and colleagues observed event rates,
defined as re-stenosis of and re-intervention on
the target vessel, at 6 months of 12 and 2% for
PTCA and MIDCAB, respectively (risk difference
10.0%, 95% CI 0.2 to 19.8%).31 No other events,
such as deaths or myocardial infarctions (MIs),
were reported. These event rates are closer to
those observed in AMIST, although the MIDCAB
rate is considerably lower.
Figure 4 shows odds ratio (OR) and risk difference
(RD) forest plots and pooled estimates for fixed-
effect meta-analyses of these three RCTs. The
pooled estimates (OR = 0.43, 95% CI 0.25 to
0.72; RD = 0.13, 95% CI 0.05 to 0.20) suggest a
statistically significant and clinically important
benefit of MIDCAB. There was no statistical
evidence of heterogeneity between the studies.
The pooled risk difference estimate is consistent
with our hypothesised difference in effectiveness
between MIDCAB and PTCA. 
The other trials did not report utility data.30,31
However, the results of the meta-analysis can be
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Chapter 5
Discussionused for a further sensitivity analysis of the cost-
effectiveness of MIDCAB versus PTCA, using
cardiac-related events rather than utility as the
measure of effectiveness. The estimated pooled
risk difference of 13% leads to an ICER of £6862
per cardiac-related event avoided. Alternatively, our
hypothesised risk difference (10%) leads to an ICER
of £8920 per cardiac-related event avoided. These
ICERs are clearly more favourable for MIDCAB
than the one based only on data from AMIST. 
Discussion
30
(a)
(b)
Odds ratio
0.01 0.1 1 10 100
Study
0.74 (0.28 to 1.95) AMIST, 2004 21.6
0.38 (0.19 to 0.74) Diegeler et al., 200230 65.2
0.15 (0.02 to 1.29) Cisowski et al., 200231 13.2
0.43 (0.25 to 0.72) Overall (95% CI)
% Weight Odds ratio
(95% CI)
Risk difference
–0.2 –0.1 0 0.1
Study
–0.06 (–0.25 to 0.13) AMIST, 2004 21.0
–0.17 (–0.28 to –0.06) Diegeler et al., 200230 54.0
–0.10 (–0.20 to –0.00) Cisowski et al., 200231 25.0
–0.13 (–0.20 to –0.05) Overall (95% CI)
% Weight Risk difference
(95% CI)
FIGURE 4 Fixed-effect meta-analyses with (a) odds ratio and (b) risk difference measures of effectConsideration of alternative
explanations for the findings
Regrettably, the much smaller than expected
sample size means that the finding of no difference
between MIDCAB and PTCA could have arisen
either because there is truly no difference between
the interventions or because the study had
insufficient power to detect the target difference of
10%. In other words, even if the underlying
difference in cardiac-related event rate was 10%,
with only 100 randomised patients the study was
unlikely to detect a significant difference.
Other sources of potential bias are confounding
factors and the unblinded nature of the outcome
assessment. Randomisation was concealed so there
should have been no opportunity for selection
bias. One participant assigned to PTCA appeared
to have been randomised after the intervention
had taken place. This patient was retained in the
analysis; if this observation truly arose because of
subversion, the selection bias would have favoured
PTCA. It is possible that there may have been
imbalances between groups by chance, because of
the small sample size, but these are taken into
account by tests of statistical inference. All
randomised patients were included in the analysis
of survival free from cardiac-related events so loss
to follow-up could not cause selection bias. The
same was not true for analyses of SAQ, CROQ, 
SF-36 and EuroQol scores, where the proportion
of randomised participants for whom responses
were available dropped to about 75% at 
12 months. However, non-response was similar in
both groups and, at 12 months, was partly
attributable to the fact that 12 months had not
elapsed from the time of the intervention for the
most recently recruited patients. 
As described, assessment of the outcomes could
not be blinded. However, the primary outcome
was assessed independently by two reviewers and
their reliability in classifying suspected events was
described. Reliability was moderate and there was
no evidence of differential bias so, at the very
worst, this method of adjudicating events might
have biased our estimate of effectiveness towards
the null hypothesis, i.e. no difference between
MIDCAB and PTCA. 
With respect to the economic evaluation, the costs
do not include hospital capital costs or overheads.
These may well have been substantial given the
difference in the intensity of service use and the
prolonged use of hospital stay for the MIDCAB.
Other cost data also need to be interpreted with
caution. In an attempt to provide data that can be
readily accessed by other researchers, we used data
from the Personal Social Services Research Unit
for staffing costs and data from the British National
Formulary for drugs. The costs of stents and other
materials were provided by the Bristol Royal
infirmary. The costs of a bed day excluding drugs,
investigations and theatre costs were also derived
from data provided by the Bristol Royal Infirmary.
Economic research to refine the cost
measurements is continuing. Nevertheless, the
sensitivity analysis suggests that the conclusion is
robust to considerable variations in costs.
Difficulties in recruiting patients
The target sample size was based on three centres
recruiting for 2 years (original proposal) or six
centres recruiting for 1 year (revised proposal).
Recruitment started in Bristol, Leicester and
Manchester in November/December 1999. St
Mary’s in London started to recruit in May 2000.
Papworth and Leeds declined to participate after
initial discussions on the revised proposal, without
giving reasons. Manchester and St Mary’s in
London stopped recruiting after 1 year because
their rates of recruitment (11 and five patients,
respectively) did not justify the investment
required for the data collection infrastructure in
these hospitals.
The total number of participants was less than
30% of the target sample size. A slower than
projected recruitment rate was inevitable given the
smaller than planned number of participating
centres. However, the rate of recruitment was also
much lower than projected in Bristol and Leicester
(and even lower in Manchester and St Mary’s).
The trial recruited 60% of patients confirmed as
eligible. Therefore, the low rate of recruitment
appears to have arisen primarily because of the
larger than expected proportion of patients with
proximal stenosis of the LAD who were ineligible.
We do not have an explanation for the large
number of patients considered to be ineligible but
note that 130 eligible patients were not
approached because the cardiologist responsible
for the patient refused or forgot to recruit them.
With hindsight, it might have been better to pay
centres a fixed sum per patient recruited, thereby
creating a financial incentive to recruit. However,
it would have been difficult for participating
centres to invest in a reliable recruitment and data
collection infrastructure without the guarantee of
funding.
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research
We have two types of recommendations as a result
of the trial. The first relates to future evaluation of
the cost-effectiveness of alternative strategies for
coronary revascularisation, given that techniques
are evolving rapidly in both interventional
cardiology and cardiac surgery. The second relates
to the possibility of carrying out secondary
research to answer the objective addressed by
AMIST.
Future primary evaluations of the 
cost-effectiveness of alternative
strategies for coronary
revascularisation
The small number of patients considered eligible
for the trial leads us to question the future of
MIDCAB. Since some patients not suitable for
PTCA might still benefit from MIDCAB, the total
number of MIDCAB operations carried out in a
tertiary cardiac surgery centre in the UK would be
likely to be greater than the number of
participants recruited to the trial per centre per
year (about 20 in Bristol and Leicester).
Nevertheless, the total number of suitable patients
is unlikely to be more than about 40 per centre
per year in UK cardiac centres such as Bristol and
Leicester. This number barely reaches the ‘critical
mass’ required to maintain surgeons’ technical
expertise in what is a technically difficult
operation. Increasingly, surgeons are using off-
pump coronary artery bypass (OPCAB) for
patients who might otherwise have undergone
MIDCAB. OPCAB, which is more effective in the
short-term and as effective as conventional CABG
in the mid-term,32 achieves many of the benefits
of MIDCAB but is technically easier and has
greater flexibility.33 Hence MIDCAB may
represent an ‘evolutionary dead end’. 
Cardiologists, who are effectively the ‘gate-keepers’
to most cardiac surgeons, regard PTCA as the
treatment of preference for proximal stenosis of
the LAD. Part of the difficulty in recruiting to
AMIST may be attributed to their reluctance to
refer such patients to cardiac surgeons if, in their
opinion, they can be treated by PTCA. This
difficulty in recruiting participants to RCTs of
interventional cardiology versus cardiac surgery
problem may become worse since, with
innovations in the technology for PTCA,
interventional cardiologists now treat some
patients with multi-vessel disease. 
Our recommendations are as follows:
  Future evaluations comparing PTCA and cardiac
surgery should focus on comparing the most
up-to-date PTCA technique with OPCAB rather
than MIDCAB.
  Such evaluations should include all categories
of patient considered suitable for PTCA, with
stratification of randomisation by key patient
subgroup, such as single/double-vessel disease.
  Commissioners of research should consider
whether a combined strategy, that is, PTCA for
one lesion and minimally invasive surgery for
another, represents a plausibly cost-effective
alternative to PTCA or surgery alone.
  Commissioners of research need to consider
how to overcome the key difficulty of recruiting
patients to evaluations comparing interventional
cardiology and cardiac surgery, given the current
gate-keeping arrangements.
Secondary research to compare the
effectiveness and cost-effectiveness of
PTCA versus MIDCAB
Through professional networks, we are aware of
other RCTs of PTCA versus MIDCAB, in addition
to those described above (see ‘Findings of the
study in the context of existing literature’, p. 29).
However, we believe that our own trial is currently
the only one to have included an economic
evaluation. Most of these trials have struggled to
recruit patients, as we did, and the data for at least
two groups remain unpublished. One research
group stopped recruiting because they were
convinced that, whatever the result of their trial
might be, it would be impossible to change
cardiologists’ preferences for treating patients with
single-vessel disease. This assertion can only be
tested by quantifying more precisely the relative
effectiveness and cost-effectiveness of PTCA and
MIDCAB and presenting the evidence to
cardiologists.
There is clearly a need for a systematic review 
and meta-analysis, if appropriate, of the existing
trials. The meta-analysis described above, which
only used published trials, may be subject to
publication bias and is, to our knowledge,
incomplete. It should therefore be repeated,
ideally using individual patient data, following a
systematic search for additional trials. 
Our recommendations are as follows:
  A systematic review and meta-analysis, if
appropriate, of existing trials should be carried
out, ideally using individual patient data. 
  The cost-effectiveness of MIDCAB should be
recalculated, applying the resource and cost
Discussion
32data from AMIST to the pooled estimate of
effectiveness determined from the systematic
review.
Conclusions
We found no evidence from AMIST that MIDCAB
is more effective than PTCA. MIDCAB was clearly
a more expensive procedure. Given the small and
non-significant differences in effectiveness between
MIDCAB and PTCA and the considerably higher
costs of MIDCAB, it is unlikely that MIDCAB
represents a cost-effective use of resources in the
reference population. Our main caution in
interpreting these findings arises from the small
sample size; a real difference in effectiveness of
the size hypothesised may exist but the trial had
insufficient power to detect it. There were few
complications with either intervention.
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Appendix 1
Recruitment figures by centreA
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Centre Weeks  Throughput Patients Patients  Refusals Patients  not  Patients  Patients Patients 
recruiting with proximal  eligible for  randomised  recruited and  not eligible for  randomised of 
stenosis of the  recruitment but agreed to  randomised recruitment total 
LAD follow-up throughput
Bristol 104 2814 209/2814 63/209 14/63 9/63 40/63 146/209 40/2814
7% 30% 22% 14% 63% 70% 1.4%
Leicester 104 6493 529/6493 68/529 16/68 8/68 44/68 461/529 44/6493
8% 13% 23% 13% 64% 87% 0.7%
London 50 1829 214/1829 11/214 6/11 0/11% 5/11 203/214 5/1829
12% 5% 55% 0% 45% 95% 0.3%
Manchester 52 1692 139/1692 25/141 4/25 10/25 11/25 114/139 11/1692
8% 18% 16% 40% 44% 82% 0.7%
Total 310 12828 1091/12828 167/1091 40/167 27/167 100/167 924/1091 100/12828
9% 15% 24% 16% 60% 85% 0.8%Health Technology Assessment 2004; Vol. 8: No. 16
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Appendix 2
Reasons given by patients for refusing to 
participate or to be randomised
Reasons given for refusing  Total number of patients refusing
To participate To be randomised
(n = 40) (n = 27)
No reason given 11 3
No reason obtained/research nurse forgot 2
Doctor rejected randomisation 2 1
Did not like idea of study 3 1
Lost confidence in the NHS 1 1
Only wants surgery (refusing PTCA) 3 2
Only wants PTCA (refusing surgery) 11 12
Could not wait for date of MIDCAB 5 5
Patient taken off waiting list 1 1
Patient sought other medical advice 1 1Health Technology Assessment 2004; Vol. 8: No. 16
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Appendix 3
CONSORT checklist of items when reporting 
a randomised controlled trial29
Section and topic Item Details of AMIST relevant to the item
Title and abstract 1 The study is described as a randomised trial in both the title and the Executive
Summary
Introduction
Background 2 The Introduction to the report describes the scientific background and rationale for
the study (pp. 1–2)
Methods
Participants 3 The ‘reference’ study population is described on pp. 3–4, including details of
inclusion and exclusion criteria. The actual study population is described in the
Results (see Participant flow, item 13)
Interventions 4 The interventions, i.e. MIDCAB and PTCA, are described on p. 6. References are
cited to other descriptions of MIDCAB
Objectives 5 The objectives and hypotheses are set out on pp. 1–2
Outcomes 6 The outcomes are described on pp. 6–7 and 11–12, including an explicit statement
of the primary outcome, i.e. the combined endpoint of survival free from death or
cardiac-related events
Sample size 7 The target sample size, and the rationale for this target are described on pp. 3–4
Randomisation 8, 9, 10 Sequence generation, allocation concealment and implementation of randomisation
are described on p. 5
Blinding 11 Details about blinding are reported on p. 7 and 11, including precautions against bias
given that outcome assessment could not be blinded
Statistical methods 12 Details of the statistical methods used are described on pp. 8–9 and 12. No
subgroup analyses were planned or carried out. For the primary outcome, both ITT
and explanatory analyses were planned
Results
Participant flow 13 A CONSORT flow chart for the trial is provided in Figure 1
Recruitment 14 Further details about recruitment are described on p. 13
Baseline data 15 Baseline data are presented in Tables 6 and 7
Numbers analysed 16 Numbers analysed for different outcomes are presented in Tables 6–9 and 12–17.
The text on p. 19 states that all randomised patients were included in the ITT
analysis of the primary outcome. A similar statement describes the numbers in the
explanatory analysis of the primary outcome, p. 19
Outcomes and  17 Outcomes are shown in Tables 12–17 and Figures 2 and 3. Confidence intervals are 
estimation reported for all estimates of effectiveness
Ancillary analyses 18 The secondary, explanatory analysis of the primary outcome measure was planned
Adverse events 19 Short-term adverse events and complications are described in Table 8, and longer-
term cardiac-related events in Table 11
Comment
Interpretation 20 Alternative explanations for the findings of the trial are described on p. 31
Generalisability 21 A statement is included on p. 29 describing our opinion on the applicability of the
trial results
Overall evidence 22 The trial findings are placed in the context of other research, and a meta-analysis of
published trials, including AMIST, is presented on pp. 29–30Health Technology Assessment 2004; Vol. 8: No. 16
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